Bharat Parenterals Q3: Standalone Revenue Dives 38.5%, Consolidated Loss Widens

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Bharat Parenterals Q3: Standalone Revenue Dives 38.5%, Consolidated Loss Widens
Overview

Bharat Parenterals reported a sharp 38.5% YoY decline in standalone revenue to ₹41.41 crore for Q3 FY26, attributed to timing headwinds and deferred institutional orders. The consolidated entity posted a wider net loss of ₹9.63 crore, impacted by ongoing R&D and operational investments in subsidiaries like Innoxel Lifesciences. Management expects a standalone revenue recovery to ₹50-55 crore in Q4 FY26, with significant uplift anticipated from H1 FY27, supported by a newly disclosed ₹303 crore order book.

📉 The Financial Deep Dive

Bharat Parenterals Limited's Q3 FY26 financial results paint a mixed picture, with significant headwinds impacting standalone operations while consolidated losses persist due to strategic investments.

The Numbers:
On a standalone basis, Revenue from Operations for Q3 FY26 stood at ₹41.41 crore, a steep 38.5% decline YoY from ₹67.34 crore in Q3 FY25. Sequentially, revenue remained flat at ₹41.70 crore in Q2 FY26. Gross Profit was ₹16.30 crore, with Gross Margins contracting to 39.4% from 43.3% in Q3 FY25 and 44.1% in Q2 FY26, reflecting a shift in product and channel mix towards exports.

EBITDA saw sequential improvement to ₹3.49 crore (8.4% margin) from ₹2.33 crore (5.6% margin) in Q2 FY26. However, YoY, EBITDA declined from ₹8.35 crore in Q3 FY25 due to the lower revenue base. Profit After Tax (PAT) was ₹1.95 crore (4.7% margin), down from ₹6.51 crore in Q3 FY25 and ₹2.72 crore in Q2 FY26. Basic Earnings Per Share (EPS) fell sharply to ₹2.78 from ₹8.30 in Q3 FY25.

The consolidated entity reported Revenue from Operations of ₹65.18 crore, a 9.8% decline YoY from ₹72.26 crore in Q3 FY25, though slightly up 0.9% QoQ from ₹64.62 crore. Consolidated EBITDA improved sequentially to ₹1.76 crore (2.7% margin) from ₹0.82 crore in Q2 FY26, but declined significantly YoY from ₹6.58 crore. The consolidated results were marred by a Net Loss of ₹9.63 crore, an increase from the net loss of ₹7.87 crore in Q3 FY25 and ₹8.60 crore in Q2 FY26. Consolidated Basic EPS stood at ₹(14.03).

The Quality:
Margin compression is evident on both standalone and consolidated fronts. The standalone gross margin decline is linked to a product and channel mix favouring exports. The consolidated net loss is attributed to ongoing R&D and operational investments within subsidiaries, particularly Innoxel Lifesciences. The incremental impact of new Labour Codes on standalone operations was ₹20.58 lakhs for gratuity and ₹14.15 lakhs for compensated absences.

🚩 Risks & Outlook:
Management anticipates a standalone revenue recovery to approximately ₹50-55 crore in Q4 FY26. However, the company will miss its earlier full-year FY26 guidance due to the timing shift in institutional order execution. The substantial order book of ₹303 crore as of December 31, 2025, is a key positive, with a meaningful portion expected to be executed in H1 FY27. This execution is critical for a significant uplift in performance. Innoxel Lifesciences' successful EU GMP inspection and FY27 PAT profitability guidance, along with Varenyam Healthcare's on-track performance for FY26, provide some strategic comfort for the subsidiaries.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.